Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Earnings beat, Revenue misses In Q4

Published 2020-01-22, 06:37 a/m
Updated 2020-01-22, 06:37 a/m
© Reuters.  J&J Earnings beat, Revenue misses In Q4

© Reuters. J&J Earnings beat, Revenue misses In Q4

Investing.com - J&J reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

J&J announced earnings per share of $1.88 on revenue of $20.75B. Analysts polled by Investing.com forecast EPS of $1.87 on revenue of $20.78B. That was in comparison with EPS of $1.97 on revenue of $20.39B in the same quarter a year earlier.J&J had announced EPS of $2.12 on revenue of $20.73B in the previous quarter.Analysts are expecting EPS of $2.27 and revenue of $20.7B in the upcoming quarter.

J&J share's are up 2.33% for the year to date and is trading at $149.27 , down-from-52-week-high.

J&J follows other major Healthcare sector earnings this month

J&J's report follows an earnings beat by Novocure Ltd on Thursday, October 31, 2019, who reported EPS of $0.02 on revenue of $92.06M, was in comparison to EPS of $-0.04 on revenue of $86.94M.

ABIOMED had beat expectations on Monday, January 13, 2020 with third quarter EPS of $1.09 on revenue of $221.6M, was in comparison with forecast for EPS of $1.07 on revenue of $226.67M.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.